Advanced Biofuel Solutions Ltd

ABSL aims to lead the development of advanced biofuel projects around the world as a project owner and supplier of technology to other organisations. Our RadGas technology is proven at scale to be more reliable and efficient than competing pathways that transform waste into fuels. Achieving net zero carbon emissions requires the replacement of fossil fuels used for heating and transport with sustainable low carbon alternatives. ABSL is at the forefront of the technical development of fuels that are made from wastes or biomass residues. Advanced biofuels can be combined with carbon sequestration technology to generate negative carbon emissions. These are essential to offset emissions from sectors such as farming and aviation that are very challenging to mitigate. ABSL’s work in this area offers the opportunity to reverse man-made global warming.

PineTree Therapeutics Inc

Pinetree Therapeutics is an award-winning, pre-clinical stage biotechnology company based in Cambridge, Massachusetts. Dedicated to addressing unmet medical needs, such as drug resistance and tumor recurrence in targeted therapy, Pinetree Therapeutics is advancing the field with its novel AbReptorTM platform. While the primary focus is on oncology, Pinetree Therapeutics is expanding pipelines to other areas as well. The AbReptorTM platform enables the development of multi-specific antibodies designed to outperform conventional inhibitors and ADCs (Antibody Drug Conjugate) by degradation. Unlike traditional inhibitors, which are limited in their mechanism of action (blocking the signaling pathway), our antibodies demonstrate superior efficacy in targeting and degrading disease proteins. The platform's focus is on targeted degradation of membrane-bound and extracellular proteins, offering a distinct advantage over conventional inhibitors and intracellular degraders like PROTACs or GLUEs. Additionally, the unique mechanism of our platform has yielded promising preclinical results in ADC (/DAC/ARC) application, demonstrating its potential to significantly advance the field.

CREATE Medicines

CREATE Medicines is a clinical-stage biotech pioneering in vivo multi-immune programming. Its proprietary mRNA-LNP platform directly programs immune cells inside the body to deliver scalable, repeat-dose, off-the-shelf immunotherapies. With proven human validation and next-generation RNA technology, CREATE is advancing a pipeline of in vivo CAR therapies to transform outcomes in cancer, autoimmunity, and fibrosis.

Bicycle Therapeutics

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company that is harnessing the power of bicyclic peptides and leveraging Nobel Prize-winning science to develop a new and differentiated class of medicines to treat cancer and other diseases. Bicycle® molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin, previously BT8009, a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radio Conjugates (BRC™) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, MA.

genomed

Genomed is committed to developing and adapting leading edge technology to application solutions for molecular diagnostic laboratories. Over 20 years’ experience in the fields of Clinical Genetics and DNA based Forensics testing has resulted in an extensive company knowledge base, putting Genomed at the forefront of these technologies. The company has two divisions: • The development, manufacture and distribution of molecular diagnostic tests • Establishing complete Turn-Key Molecular Laboratories